

(19)



(11)

**EP 1 928 523 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**21.07.2010 Bulletin 2010/29**

(51) Int Cl.:  
**A61M 5/20 (2006.01)**

(21) Application number: **05787023.0**

(86) International application number:  
**PCT/GB2005/003725**

(22) Date of filing: **27.09.2005**

(87) International publication number:  
**WO 2007/036676 (05.04.2007 Gazette 2007/14)**

(54) **AUTO-INJECTION DEVICE WITH NEEDLE PROTECTING CAP HAVING OUTER AND INNER SLEEVES**

AUTOMATISCHE INJEKTIONSVORRICHTUNG MIT NADELSCHUTZKAPPE MIT AUSSEN- UND INNENHÜLSEN

DISPOSITIF D AUTO-INJECTION DOTE D UN EMBOUT DE PROTECTION D AIGUILLE  
COMPORTANT DES DOUILLES EXTERIEURE ET INTERIEURE

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI  
SK TR**

(43) Date of publication of application:  
**11.06.2008 Bulletin 2008/24**

(73) Proprietor: **Cilag GmbH International  
6300 Zug (CH)**

(72) Inventors:  
• **HABESHAW, Rosie, Louise  
Cambridge CB1 7TS (GB)**

• **JOHNSTON, David, Maxwell  
NJ 08691 (US)**

(74) Representative: **Tunstall, Christopher Stephen et  
al  
Carpmaels & Ransford  
43-45 Bloomsbury Square  
London WC1A 2RA (GB)**

(56) References cited:  
**EP-A- 0 516 473 EP-A- 0 824 923  
WO-A-2005/070481 US-A- 5 599 309  
US-A- 6 077 247 US-A- 2005 049 561  
US-A1- 2004 153 033 US-A1- 2005 203 466  
US-B1- 6 203 530**

**EP 1 928 523 B1**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

## Description

### Background Technology

**[0001]** The present invention relates to an injection device of the type that receives a syringe, extends it, discharges its contents and then retracts it automatically. Devices of this general description are shown in US 5,599,309; WO 95/35126, WO 05/070481 and EP-A-0 516 473 and tend to employ a drive spring and some form of release mechanism that releases the syringe from the influence of the drive spring once its contents are supposed to have been discharged, to allow it to be retracted by a return spring.

**[0002]** Generally, the return spring is relatively weak, since its restoring force must be overcome by the drive spring, even while the drive spring is doing work on the various components of the injector device and the syringe during an injection cycle. This may give rise to a problem when the injection device is used with sealed hypodermic syringes, which typically have a hermetically sealed cover or "boot" that covers the hypodermic needle and maintains the sterility of the syringe contents. Naturally, it is necessary to maintain the sterility of the syringe contents up to the point of administration, which devices that are designed to be disposable, as many will be, means that the boot must be removed with the syringe inside the injection device.

**[0003]** Typically, the action required to remove the boot from the syringe is simply to pull the boot away from the syringe, which requires a force in excess of 20N. This is significantly greater than the restoring force of the return spring, so the syringe will be pulled out of the injection device as the boot is removed and, when the boot comes away, it will snap back into place. This is not the best way to handle the syringe. The shock could damage it, the needle could be damaged and there may be problems re-engaging the syringe with those components of the injection device designed to act upon it. Even in cases where there is no return spring, such as in the devices taught in US 2005/0203466 and US 6,077,247, where the syringe is held in place by friction with components of the injection device, the problem will still arise of relocating the syringe onto those components of the injection device designed to act upon it.

### Summary of the Invention

**[0004]** The injection devices of the present invention are designed to deal with these problems.

**[0005]** An injection device according to a first aspect of the invention comprises: a housing adapted to receive a syringe having a discharge nozzle and having a boot that covers its discharge nozzle, so that the syringe is movable between a retracted position in which the discharge nozzle is contained within the housing and an extended position in which the discharge nozzle extends from the housing through an exit aperture, the housing

including means for biasing the syringe from its extended position to its retracted position; a releasable locking mechanism that retains the syringe in its retracted position; and a housing closure member that can occupy a first position, in which it locates on the housing and prevents the locking mechanism from being released, and a second position, in which it does not prevent the locking mechanism from being released, the first position of the housing closure member being one in which it engages the boot, so that movement of the housing closure member to its second position results in removal of the boot from the syringe. The device further comprises an actuator; a drive that is acted upon by the actuator and in turn acts upon the syringe to advance it from its retracted position to its extended position and discharge its contents through the discharge nozzle; a release mechanism operable to release the locking mechanism, thus allowing the syringe to be advanced by the actuator from its retracted position to its extended position, and in which the first position or the housing closure member is one in which it prevents the release mechanism from being operated; and a return mechanism, activated when the drive has reached a nominal return position, to release the syringe from the action of the actuator, whereupon the biasing means restores the syringe to its retracted position. The locking mechanism is characterised in that it comprises a latch member that is located within the housing and is biased into a position in which it engages a locking surface. The release mechanism moves it from that position into a position in which it no longer engages the locking surface.

**[0006]** When the housing closure member is in its first position, it not only locates on the housing and engages the boot, but it also prevents the locking mechanism from being released. Thus, the syringe is locked into its retracted position and cannot be driven forwards. When the housing closure member is moved, it takes the boot with it, during which process the locking mechanism still prevents the syringe from moving. Afterwards, the locking mechanism can be released as required, allowing the syringe to be driven forwards when the device is used. Therefore, the syringe can move forwards only once the boot has been removed, not during its removal.

**[0007]** Preferably, when the housing closure member is in its first position, it closes the exit aperture to the discharge nozzle. For convenience, the closure member may be removable. In other words, the first position of the housing closure member is one in which it locates on the housing and the second position is one in which it does not. For example, the housing closure member could be a cap that locates onto the housing by means of a thread.

**[0008]** The release mechanism may be a primary member movable between locking and releasing positions, the first position of the housing closure member being one in which it covers the primary member.

**[0009]** A particularly effective arrangement is one in which the locking position of the primary member is one

in which it projects from the exit aperture and the releasing position is one in which it does not project from the exit aperture or projects from it to a lesser extent. This means that the primary member may be moved from its locking position to its releasing positions by bringing the end of the injection device into contact with the skin at the injection site. Apart from anything else, this ensures that the injection device is optimally positioned relative to the injection site before the injection cycle can begin. A primary member in the form of a sleeve allows a relatively large area to contact the skin and allows the discharge nozzle of the syringe to be advanced and retracted within it. In the case of a hypodermic syringe, the sleeve will shroud the needle from view, which is a good idea for the squeamish, particularly those who have to administer to themselves.

**[0010]** The primary member mentioned above may include a latch opening through which the latch member projects before it engages the locking surface, the primary member acting as a cam and the latch member as a cam follower, so that movement of the primary member from its locking position to its releasing position causes the latch member to disengage from the locking surface. The latch member may include a ramped surface against which a surface of the primary member acts to disengage it from the locking surface.

**[0011]** The injection device may further comprise a trigger movable from a rest position, in which it causes the drive to be retained in a positions corresponding to the retracted position of the syringe, to an active position, in which it no longer causes the drive to be so retained, thus allowing it to be advanced by the actuator and in turn to advance the syringe, from its retracted position to its extended position and discharge its contents through the discharge nozzle; and an interlock member movable between a locking position, at which it prevents movement of the trigger from its rest position to its active position, and a releasing position, at which it allows movement of the trigger from its rest position to its active position, the trigger thereafter being retained in its active positions.

**[0012]** Such a device provides a visual indication that it is either ready to use or has been used. If it is ready for use, the trigger will be in its rest position. If it has been used, the trigger will be in its active position. These positions can be discriminated by the user. Moreover, the device incorporated the mechanism for achieving this result into a safety interlock mechanism, in the interests of simplicity. The trigger may comprise a locking member that, in the rest position of the trigger, engages a locking surface of the drive and, in the active position, does not.

**[0013]** The interlock member may comprise a primary member, the locking position of the interlock member being one in which the primary member projects from the exit aperture and the releasing position being one in which the primary member does not project from the exit aperture or projects from it to a lesser extent. This means that the interlock member may be moved from its locking position to its releasing position by bringing the end of

the injection device into contact with the skin at the injection site. Apart from anything else, this ensures that the injection device is optimally positioned relative to the injection site before the injection cycle can begin. A primary member in the form of a sleeve allows a relatively large area to contact the skin and allows the discharge nozzle of the syringe to be advanced and retracted within it. In the case of a hypodermic syringe, the sleeve will shroud the needle from view, which is a good idea for the squeamish, particularly those who have to administer to themselves.

**[0014]** The locking of the trigger in its rest position may be achieved as follows. The trigger and the interlock member include a projection and an aperture, the projection being in register with the aperture when the interlock member is in its releasing position, but not otherwise. This allows the trigger to move from its rest position to its active position by movement of the projection into the aperture. The projection may be on the trigger and the aperture is in the interlock member.

**[0015]** The retention of the trigger in its active position may be achieved as follows. The trigger and another component of the device include a latching projection and a corresponding latching surface against which the latching projection latches when the trigger is in its active position. The latching projection may be on the trigger. This other component of the device is preferably the interlock member.

#### Brief Description of the Drawings

**[0016]** The invention will now be described by way of example with reference to the accompanying drawings, in which:

Figure 1 shows the end of an injection device before a cap is affixed to it;  
 Figure 2 shows it once the cap has been affixed;  
 Figure 3 shows in section a device with the cap affixed;  
 Figure 4 shows in section a device after the cap has been removed; and  
 Figure 5 is an enlarged cut-out from figure 4.  
 Figure 6 shows in sectional schematic how an injection device may be further modified;  
 Figure 7 is a cut-away view of such a modified injection device; and  
 Figure 8 shows in section a preferred injection device.

#### Detailed Description

**[0017]** Fig. 1 shows the end of an injection device housing 112 and a cap 111. Other parts of the device will be described in greater detail below, but it will be seen that the cap 111 includes a thread 113 that cooperates with a corresponding thread 115 on the end of the housing. The end of the housing 112 has an exit aperture 128,

from which the end of a sleeve 119 can be seen to emerge. The cap 111 has a central boss 121 that fits within the sleeve 119 when the cap 111 is installed on the housing 112, as can be seen in fig. 2.

**[0018]** Fig. 3 shows an injection device 110 in more detail. The housing 112 contains a hypodermic syringe 114 of conventional types including a syringe body 116 terminating at one end in a hypodermic needle 118 and at the other in a flange 120. The conventional plunger that would normally be used to discharge the contents of the syringe 114 manually has been removed and replaced with a drive element 134 that terminates in a bung 122. The bung 122 constrains a drug 124 to be administered within the syringe body 116. Whilst the syringe illustrated is of hypodermic type, this need not necessarily be so. Transcutaneous or ballistic dermal and subcutaneous syringes may also be used with the injection device of the present invention. As illustrated, the housing includes a return spring 126 that biases the syringe 114 from an extended position in which the needle 118 extends from an aperture 128 in the housing 112 to a retracted position in which the discharge nozzle 118 is contained within the housing 112. The return spring 126 acts on the syringe 114 via a syringe carrier 127.

**[0019]** At the other end of the housing is an actuator, which here takes the form of a compression drive spring 130. Drive from the drive spring 130 is transmitted via a multi-component drive to the syringe 114 to advance it from its retracted position to its extended position and discharge its contents through the needle 118. The drive accomplishes this task by acting directly on the drug 124 and the syringe 114. Hydrostatic forces acting through the drug 124 and, to a lesser extent, static friction between the bung 122 and the syringe body 116 initially ensure that they advance together, until the return spring 126 bottoms out or the syringe body 116 meets some other obstruction (not shown) that retards its motion.

**[0020]** The multi-component drive between the drive spring 130 and the syringe 114 consists of three principal components. A drive sleeve 131 takes drive from the drive spring 130 and transmits it to flexible latch arms 133 on a first drive element 132. This in turn transmits drive via flexible latch arms 135 to a second drive element, the drive element 134 already mentioned.

**[0021]** The first drive element 132 includes a hollow stem 140, the inner cavity of which forms a collection chamber 142 in communication with a vent 144 that extends from the collection chamber through the end of the stem 140. The second drive element 134 includes a blind bore 146 that is open at one end to receive the stem 140 and closed at the other. As can be seen, the bore 146 and the stem 140 defining a fluid reservoir 148, within which a damping fluid is contained.

**[0022]** A trigger (not shown) is provided that, when operated, serves to decouple the drive sleeve 131 from the housing 112, allowing it to move relative to the housing 112 under the influence of the drive spring 130. The operation of the device is then as follows.

**[0023]** Initially, the drive spring 130 moves the drive sleeve 131, the drive sleeve 131 moves the first drive element 32 and the first drive element 132 moves the second drive element 134, in each case by acting through the flexible latch arms 133, 135. The second drive element 134 moves and, by virtue of static friction and hydrostatic forces acting through the drug 124 to be administered, moves the syringe body 116 against the action of the return spring 126. The return spring 126 compresses and the hypodermic needle 118 emerges from the exit aperture 128 of the housing 112. This continues until the return spring 126 bottoms out or the syringe body 116 meets some other obstruction (not shown) that retards its motion. Because the static friction between the second drive element 134 and the syringe body 116 and the hydrostatic forces acting through the drug 124 to be administered are not sufficient to resist the full drive force developed by the drive spring 130, at this point the second drive element 134 begins to move within the syringe body 116 and the drug 124 begins to be discharged. Dynamic friction between the second drive element 134 and the syringe body 116 and hydrostatic forces acting through the drug 124 to be administered are, however, sufficient to retain the return spring 126 in its compressed state, so the hypodermic needle 118 remains extended.

**[0024]** Before the second drive element 134 reaches the end of its travel within the syringe body 116, so before the contents of the syringe have fully discharged, the flexible latch arms 135 linking the first and second drive elements 132, 134 reach a constriction 137 within the housing 112. The constriction 137 moves the flexible latch arms 135 inwards from the position shown to a position at which they no longer couple the first drive element 132 to the second drive element 134, aided by the bevelled surfaces on the constriction 137. Once this happens, the first drive element 132 acts no longer on the second drive element 134, allowing the first drive element 132 to move relative to the second drive element 134.

**[0025]** Because the damping fluid is contained within a reservoir 148 defined between the end of the first drive element 132 and the blind bore 146 in the second drive element 134, the volume of the reservoir 146 will tend to decrease as the first drive element 132 moves relative to the second drive element 134 when the former is acted upon by the drive spring 130. As the reservoir 148 collapses, damping fluid is forced through the vent 144 into the collection chamber 142. Thus, once the flexible latch arms 135 have been released, the force exerted by the drive spring 130 does work on the damping fluid, causing it to flow through the constriction formed by the vent 144, and also acts hydrostatically through the fluid and through friction between the first and second drive elements 132, 134, thence via the second drive element 134. Losses associated with the flow of the damping fluid do not attenuate the force acting on the body of the syringe to a great extent. Thus, the return spring 126 remains compressed and the hypodermic needle remains extended.

**[0026]** After a time, the second drive element 134 completes its travel within the syringe body 116 and can go no further. At this point, the contents of the syringe 114 are completely discharged and the force exerted by the drive spring 130 acts to retain the second drive element 134 in its terminal position and to continue to cause the damping fluid to flow through the vent 144, allowing the first drive element 132 to continue its movement.

**[0027]** Before the reservoir 148 of fluid is exhausted, the flexible latch arms 133 linking the drive sleeve 131 with the first drive element 132 reach another constriction 139 within the housing 112. The constriction 139 moves the flexible latch arms 133 inwards from the position shown to a position at which they no longer couple the drive sleeve 131 to the first drive element 132, aided by the bevelled surfaces on the constriction 139. Once this happens, the drive sleeve 131 acts no longer on the first drive element 132, allowing them to move relative each other. At this point, of course, the syringe 114 is released, because the forces developed by the drive spring 130 are no longer being transmitted to the syringe 114, and the only force acting on the syringe will be the return force from the return spring 126. Thus, the syringe 114 is now returned to its retracted position and the injection cycle is complete.

**[0028]** All this takes place, of course, only once the cap 111 has been removed from the end of the housing 112. As can be seen from fig. 3, the end of the syringe is sealed with a boot 123. The central boss 121 of the cap that fits within the sleeve 119 when the cap 111 is installed on the housing 112, is hollow at the end and the lip 125 of the hollow end is bevelled on its leading edge 157, but not its trailing edge. Thus, as the cap 111 is installed, the leading edge 157 of the lip 125 rides over a shoulder 159 on the boot 123. However, as the cap 111 is removed, the trailing edge of the lip 125 will not ride over the shoulder 159, which means that the boot 123 is pulled off the syringe 114 as the cap 111 is removed.

**[0029]** Meanwhile, as can best be seen in figs. 4 and 5, the syringe carrier 127, with respect to which the syringe 114 cannot move, is prevented from movement by a resilient latch member 161 that is located within the housing 112 and is biased into a position in which it engages a locking surface 163 of a syringe carrier 127. Before engaging the locking surface 163, the latch member 161 also extends through a latch opening 165 in the sleeve 119, the end of which projects from the exit aperture 128. The latch member 161 includes a ramped surface 167 against which an edge 171 of the latch opening 165 acts in the manner of a cam acting on a cam follower. Thus, movement of the sleeve 119 in a direction into the housing 112, or in other words depression of the projecting end of the sleeve, brings the edge 171 of the latch opening 165 into contact with the ramped surface 167 of the latch member 161 and further depression causes the latch member 161 to move outwards and thus to disengage from the locking surface 163. The sleeve 119 may

be depressed by bringing the end of the injection device into contact with the skin at an injection site. Once the latch member 161 has disengaged from the locking surface 163, the syringe carrier 127 is free to move as required under the influence of the actuator and drive.

**[0030]** Figs. 6 and 7 show the device may be further modified. Although figs. 6 and 7 differ from figs. 4 and 5 in some details, the principles now discussed are applicable to the device shown in figs. 4 and 5. As can be seen, the device includes a trigger 300 having a button 302 at one end and a pair of lugs 304 that cooperate with pins (not shown) on the inside of the housing 112 to allow the trigger to pivot about an axis through the two lugs 304. The main body portion of the trigger 300, to which both the button 302 and the lugs 304 are affixed, forms a locking member 306. In the position shown, the end of the locking member 306 remote from the button 302 engages the end of the drive sleeve 131, against which the drive spring 130 acts and which in turn acts upon the multi-component drive previously discussed. This prevents the drive sleeve 131 from moving under the influence of the drive spring 130. When the button 302 is depressed, the trigger 300 pivots about the lugs 304, which lifts the end of the locking member 306 from its engagement with the drive sleeve 131, now allowing the drive sleeve 131 to move under the influence of the drive spring 130.

**[0031]** Fig. 7 shows the exit aperture 128 in the end of the housing 112, from which the end of the sleeve 119 can again be seen to emerge. As is shown in fig. 6, the sleeve 119 is coupled to a button lock 310 which moves together with the sleeve 119. The trigger includes a stop pin 312 and the button lock 310 includes a stop aperture 314 which, as shown in fig. 6, are out of register. They can, however, be brought into register by inward movement of the sleeve 119, which results in a corresponding movement of the button lock 310. Whilst the stop pin 312 and the stop aperture 314 are out of register, the button 302 may not be depressed; once they are in register, it may. The trigger 300 also includes a flexible, barbed latching projection 316 and the button lock 310 also includes a latching surface 318 with which the latching projection 316 engages when the button is depressed. Once the latching projection 316 has latched with the latching surface 318, the trigger 300 is permanently retained with the button 302 in its depressed position.

**[0032]** Thus, movement of the sleeve 119 in a direction into the housing 112, or in other words depression of the projecting end of the sleeve, brings the stop pin 312 into register with the stop aperture 314, allowing the trigger button 302 to be depressed, whereupon it is retained in its depressed position by the latching projection 316 and the latching surface 318. The sleeve 119 may be depressed by bringing the end of the injection device into contact with the skin at an injection site which, apart from anything else, ensures it is properly positioned before the injection cycle begins.

**[0033]** The use of the sleeve 119 both the release and

lock the trigger 300 and to allow the syringe carrier 127 to move, together with a boot-removing cap 111 that prevents the sleeve 119 from being depressed results in an integrated injection device of elegant design.

**[0034]** Figure 8 shows a preferred injection device 210 to which the improvements described above with reference to Figures 6 and 7 are applied. Again, a housing 212 contains a hypodermic syringe 214. The syringe 214 is again of conventional type, including a syringe body 216 terminating at one end in a hypodermic needle 218 and at the other in a flange 220, and a rubber bung 222 that constraint a drug 224 to be administered within the syringe body 216. The conventional plunger that would normally be connected to the bung 222 and used to discharge the contents of the syringe 214 manually, has been removed and replaced with a multi-component drive element as will be described below. Whilst the syringe illustrated is again of hypodermic type, this need not necessarily be so. As illustrated, the housing includes a return spring 226 that biases the syringe 214 from an extended position in which the needle 218 extends from aperture 228 in the housing 212, to a retracted position in which the hypodermic needle 218 is contained within the housing 212. The return spring 226 acts on the syringe 214 via a sleeve 227.

**[0035]** At the other end of the housing is a compression drive spring 230. Drive from the drive spring 230 this transmitted via the multi-component drive to the syringe 214 to advance it from its retracted position to its extended position and discharge its contents through the needle 218. The drive accomplishes this task by acting directly on the drug 224 and the syringe 214. Hydrostatic forces acting through the drug 224 and, to a lesser extent, static friction between the bung 222 and the syringe body 216 initially ensure that they advance together, until the return spring 226 bottoms out or the syringe body 216 meets some other obstruction that retards its motion.

**[0036]** The multi component drive between the drive spring 230 and the syringe 214 again consists of three principal components. The drive sleeve 231 takes drive from the drive spring 230 and transmits it to flexible latch arms 233 on a first drive element 232. These elements are shown in detail "A". The first drive element 232 in turn transmits drive via flexible latch arms 235 to a second drive element 234. These elements are shown in detail "B". As before, the first drive element 232 includes a hollow stem 240, the inner cavity of which forms a collection chamber 242. The second drive element 234 includes a blind for 246 that is open at one end to receive the stem 240 and closed at the other. As can be seen, the bore 246 and the stem 240 define a fluid reservoir 248, within which a damping fluid is contained.

**[0037]** A trigger as described above with reference to figures 6 and 7 is provided in the middle of the housing 212. The trigger, once operated, serves to decouple the drive sleeve 231 from the housing 212 allowing it to move relative to the housing 212 under the influence of the drive spring 230. The operation of the device is then as

follows.

**[0038]** Initially, the drive spring 230 moves the drive sleeve 231, the drive sleeve 231 moves the first drive element 232 and the first drive element 232 moves the second drive element 234, in each case by acting through the flexible matching arms 233, 235. The second drive element 234 moves and, by virtue of static friction and hydrostatic forces acting through the drug 224 to be administered, moves the syringe body 216 against the action of the return spring 226. The return spring 226 compresses and the hypodermic needle 218 emerges from the exit aperture 228 of the housing 212. This continues until the return spring 226 bottoms out or the syringe body 216 meets some other obstruction that retards its motion. Because the static friction between the bung 222 and the syringe body 216 and the hydrostatic forces acting through the drug 224 to be administered are not sufficient to resist the full drive force developed by the drive spring 230, at this point the second drive element 234 begins to move within the syringe body 216 and the drug 224 begins to be discharged. Dynamic friction between the bung 222 and the syringe body 216 and hydrostatic forces acting through the drug 224 to be administered are, however, sufficient to retain the return spring 226 in its compressed state, so the hypodermic needle 218 remains extended.

**[0039]** Before the second drive element 234 reaches the end of its travel within the syringe body 216, so before the contents of the syringe have fully discharged, the flexible latch arms 235 linking the first and second drive elements 232, 234 reach a constriction 237. The constriction 237 is formed by a component 262 that is initially free to move relative to all other components, but that is constrained between the syringe flange 220 and additional flexible arms 247 on the second drive element 234. These additional flexible arms 247 overlie the flexible arms 235 on the first drive element 232, by means of which drive is transmitted to the second drive element 234. Figure 3 illustrates the injection device 210 at the position where the additional flexible arms 247 are just making contact with the constriction 237 in the component 262.

**[0040]** The constriction 237 moves the additional flexible arms 247 inwards, aided by the bevelled surfaces on both, and the additional flexible arms 247 in turn move the flexible arms 235, by means of which drive is transmitted from the first drive element 232 to the second drive element 234, inwards from the position shown to a position at which they no longer couple the first and second drive elements together. Once this happens, the first drive element 232 acts no longer on the second drive element 234, allowing the first drive element 232 to move relative to the second drive element 234.

**[0041]** Because the damping fluid is contained within a reservoir 248 defined between the end of the first drive element 232 and the blind bore 246 in the second drive element 234, the volume of the reservoir 248 will tend to decrease as the first drive element 232 moves relative

to the second drive element 234 when the former is acted upon by the drive spring 230. As the reservoir 248 collapses, damping fluid is forced into the collection chamber 242. Thus, once the flexible latch arms 235 have been released, the force exerted by the drive spring 230 does work on the damping fluid, causing it to flow into the collection chamber 242, and also acts hydrostatically through the fluid and through friction between the first and second drive elements 232, 234, thence via the second drive element 234. Losses associated with the flow of the damping fluid do not attenuate the force acting on the body of the syringe to a great extent. Thus, the return spring 226 remains compressed and the hypodermic needle remains extended.

**[0042]** After a time, the second drive element 234 completes its travel within the syringe body 216 and can go no further. At this point, the contents of the syringe 214 are completely discharged and the force exerted by the drive spring 230 acts to retain the second drive element 234 in its terminal position and to continue to cause the damping fluid to flow into the collection chamber 142, allowing the first drive element 232 to continue its movement.

**[0043]** A flange 270 on the rear of the second drive element 234 normally retains the flexible arms 233 in engagement with the drive sleeve 231. However, before the reservoir 248 of damping fluid is exhausted, the flexible latch arms 233 linking the drive sleeve 231 with the first drive element 232 move sufficiently far forward relative to the second drive element 234 that the flange 270 is brought to register with a rebate 272 in the flexible arms 233, whereupon it ceases to be effective in retaining the flexible arms 233 in engagement with the drive sleeve 231. Now, the drive sleeve 231 moves the flexible latch arms 233 inwards from the position shown to a position at which they no longer couple the drive sleeve 231 to the first drive element 232, aided by the bevelled latching surfaces 274 on the flexible arms 233. Once this happens, the drive sleeve 231 acts no longer on the first drive element 232, allowing them to move relative to each other. At this point, of course, the syringe 214 is released, because the forces developed by the drive spring 230 are no longer being transmitted to the syringe 214, and the only force acting on the syringe will be the return force from the return spring 226. Thus, the syringe 214 now returns to its retracted position and the injection cycle is complete.

## Claims

### 1. An injection device comprising:

a housing (112) adapted to receive a syringe (114) having a discharge nozzle (118) and having a boot (123) that covers its discharge nozzle, so that the syringe is movable between a retracted position in which the discharge nozzle is con-

tained within the housing and an extended position in which the discharge nozzle extends from the housing through an exit aperture (128), the housing including means for biasing (126) the syringe from its extended position to its retracted position;

a releasable locking mechanism that retains the syringe in its retracted position; and

a housing closure member (111) that can occupy a first position, in which it locates on the housing and prevents the locking mechanism from being released, and a second position, in which it does not prevent the locking mechanism from being released, the first position of the housing closure member being one in which it engages the boot, so that movement of the housing closure member to its second position results in removal of the boot from the syringe;

an actuator (130);

a drive (131) that is acted upon by the actuator and in turn acts upon the syringe to advance it from its retracted position to its extended position and discharge its contents through the discharge nozzle;

a release mechanism operable to release the locking mechanism, thus allowing the syringe to be advanced by the actuator from its retracted position to its extended position, and in which the first position of the housing closure member is one in which it prevents the release mechanism from being operated; and

a return mechanism, activated when the drive has reached a nominal return position, to release the syringe from the action of the actuator, whereupon the biasing means restores the syringe to its retracted position; **characterised in that:**

the locking mechanism comprises a latch member (161) that is located within the housing and is biased into a position in which it engages a locking surface (163) and the release mechanism moves it from that position into a position in which it no longer engages the locking surface.

2. An injection device according to claim 1 in which the first position of the housing closure member is one in which it closes the exit aperture to the discharge nozzle, and the second position is one in which it does not.

3. An injection device according to claim 1 or claim 2 in which the first position of the housing closure member is one in which it locates on the housing and the second position is one in which it does not.

4. An injection device according to any preceding claim

in which the housing closure member is a cap (111) that locates onto the housing.

5. An injection device according to claim 1 in which the release mechanism is a primary member (119) movable between locking and releasing positions and in which the first position of the housing closure member is one in which it covers the primary member. 5
6. An injection device according to claim 5 in which the locking position of the primary member is one in which it projects from the exit aperture and the releasing position is one in which it does not project from the exit aperture or projects from it to a lesser extent. 10 15
7. An injection device according to claim 6 in which the primary member is a sleeve (119).
8. An injection device according to claim 6 or claim 7 in which the primary member includes a latch opening (165) through which the latch member projects before it engages the locking surface, the primary member acting as a cam and the latch member as a cam follower, so that movement of the primary member from its locking position to its releasing position causes the latch member to disengage from the locking surface. 20 25
9. An injection device according to claim 8 in which the latch member includes a ramped surface (167) against which a surface of the primary member acts to disengage it from the locking surface. 30
10. An injection device according to any one of claims 1-7 further comprising: 35
 

a trigger movable from a rest position, in which it causes the drive to be retained in a position corresponding to the retracted position of the syringe, to an active position, in which it no longer causes the drive to be so retained, thus allowing it to be advanced by the actuator and in turn to advance the syringe from its retracted position to its extended position and discharge its contents through the discharge nozzle; and an interlock member movable between a locking position, at which it prevents movement of the trigger from its rest position to its active position, and a releasing position, at which it allows movement of the trigger from its rest position to its active position, the trigger thereafter being retained in its active position. 40 45 50
11. An injection device according to any one of claims 5-7 further comprising: 55
 

a trigger movable from a rest position, in which

it causes the drive to be retained in a position corresponding to the retracted position of the syringe, to an operative position, in which it no longer causes the drive to be so retained, thus allowing it to be advanced by the actuator and in turn to advance the syringe from its retracted position to its extended position and discharge its contents through the discharge nozzle; and an interlock member comprising the primary member, the interlock member being movable between a locking position, at which it prevents movement of the trigger from its rest position to its active position and the primary member projects from the exit aperture, and a releasing position, at which it allows movement of the trigger from its rest position to its active position and the primary member does not project from the exit aperture or projects from it to a lesser extent, the trigger thereafter being retained in its active position.

12. An injection device according to claim 10 or claim 11, in which the trigger comprises a locking member that, in the rest position of the trigger, engages a locking surface of the drive and, in the active position, does not.
13. An injection device according to any one of claims 10-12 in which the trigger and the interlock member include a projection and an aperture, the projection being in register with the aperture when the interlock member is in its releasing position, but not otherwise, thus allowing the trigger to move from its rest position to its active position by movement of the projection into the aperture.
14. An injection device according to claim 13 in which the projection is on the trigger and the aperture is in the interlock member.
15. An injection device according to any one of claims 10-14 in which the trigger and another component of the device include a latching projection and a corresponding latching surface against which the latching projection latches when the trigger is in its active position.
16. An injection device according to claim 15 in which the latching projection is on the trigger.
17. An injection device according to claim 15 or claim 16 in which the said other component of the device is the interlock member.

#### Patentansprüche

1. Injektionsvorrichtung, die aufweist:



ein Gehäuse (112), das dazu ausgelegt ist, eine Injektionsspritze (114) aufzunehmen, welche eine Auslassdüse (118) hat und welche eine Schutzmanschette (123) hat, die ihre Auslassdüse überdeckt, so dass die Injektionsspritze zwischen einer zurückgezogenen Position, in der die Auslassdüse in dem Gehäuse enthalten ist, und einer ausgefahrenen Position, in der sich die Auslassdüse aus dem Gehäuse durch eine Austrittsöffnung (128) erstreckt, bewegbar ist, wobei das Gehäuse eine Einrichtung (126) zum Vorbelasten der Injektionsspritze aus ihrer ausgefahrenen Position in ihre zurückgezogene Position umfasst;

einen freigebbaren Sperrmechanismus, der die Injektionsspritze in ihrer zurückgezogenen Position hält; und

ein Gehäuseschließelement (111), das eine erste Position, in der es sich auf dem Gehäuse befindet und verhindert, dass der Sperrmechanismus freigegeben wird, und eine zweite Position, in der es nicht verhindert, dass der Sperrmechanismus freigegeben wird, besetzen kann, wobei die erste Position des Gehäuseschließelementes eine ist, in der es an der Schutzmanschette angreift, so dass die Bewegung des Gehäuseschließelementes in seine zweite Position zum Entfernen der Schutzmanschette von der Injektionsspritze führt;

ein Betätigungselement (130);

ein Treiberelement (131), auf das von dem Betätigungselement eingewirkt wird und das wiederum auf die Injektionsspritze einwirkt, um sie aus ihrer zurückgezogenen Position in ihre ausgefahrene Position vorzubewegen und ihre Inhalte durch die Auslassdüse auszugeben;

einen Freigabemechanismus, der so betreibbar ist, dass er den Sperrmechanismus freigibt, so dass es möglich wird, dass die Injektionsspritze von dem Betätigungselement aus ihrer zurückgezogenen Position in ihre ausgefahrene Position vorbewegt wird, und wobei die erste Position des Gehäuseschließelementes eine ist, in der es verhindert, dass der Freigabemechanismus betätigt wird; und

einen Rückführmechanismus, der aktiviert wird, wenn das Treiberelement eine nominale Rückkehrposition erreicht hat, um die Injektionsspritze von der Wirkung des Betätigungselementes zu befreien, woraufhin die vorbelastende Einrichtung (126) die Injektionsspritze in ihre zurückgezogene Position zurückführt; **dadurch gekennzeichnet, dass:**

der Sperrmechanismus ein Klinkenelement (161) aufweist, das sich innerhalb des Gehäuses befindet und in eine Position vorbelastet ist, in der es mit einer Sperrfläche

(163) im Eingriff ist, und der Freigabemechanismus es aus dieser Position in eine Position, in der es nicht mehr mit der Sperrfläche im Eingriff ist, bewegt.

2. Injektionsvorrichtung nach Anspruch 1, bei der die erste Position des Gehäuseschließelementes eine ist, in der es die Austrittsöffnung für die Auslassdüse verschließt, und die zweite Position eine ist, in der es dieses nicht tut.
3. Injektionsvorrichtung nach Anspruch 1 oder Anspruch 2, bei der die erste Position des Gehäuseschließelementes eine ist, in der es sich auf dem Gehäuse befindet, und die zweite Position eine ist, in der es dieses nicht ist.
4. Injektionsvorrichtung nach einem der vorangehenden Ansprüche, bei der das Gehäuseschließelement eine Kappe (111) ist, die sich auf dem Gehäuse befindet.
5. Injektionsvorrichtung nach Anspruch 1, bei der der Freigabemechanismus ein Primärelement (119) ist, das zwischen der Sperr- und der Freigabeposition bewegbar ist, und bei der die erste Position des Gehäuseschließelementes eine ist, in der es das Primärelement abdeckt.
6. Injektionsvorrichtung nach Anspruch 5, bei der die Sperrposition des Primärelementes eine ist, in der es aus der Austrittsöffnung ragt, und die Freigabeposition eine ist, in der es nicht aus der Austrittsöffnung ragt oder in einem geringeren Ausmaße daraus ragt.
7. Injektionsvorrichtung nach Anspruch 6, bei der das Primärelement eine Hülse (119) ist.
8. Injektionsvorrichtung nach Anspruch 6 oder Anspruch 7, bei der das Primärelement eine Klinkenöffnung (165) umfasst, durch die das Klinkenelement ragt, bevor es in Eingriff mit der Sperrfläche kommt, wobei das Primärelement als ein Nocken und das Klinkenelement als ein Nockenmitnehmer wirkt, so dass die Bewegung des Primärelementes aus seiner Sperrposition in seine Freigabeposition bewirkt, dass sich das Klinkenelement von der Sperrfläche löst.
9. Injektionsvorrichtung nach Anspruch 8, bei der das Klinkenelement eine Rampenfläche (167) umfasst, gegen die eine Oberfläche des Primärelementes wirkt, um es von der Sperrfläche zu lösen.
10. Injektionsvorrichtung nach einem der Ansprüche 1-7, die weiter aufweist:

einen Auslöser, der aus einer Ruheposition, in der er bewirkt, dass das Treiberelement in einer Position, die der zurückgezogenen Position der Injektionsspritze entspricht, gehalten wird, in eine aktive Position, in der er nicht länger bewirkt, dass das Treiberelement derart zurückgehalten wird, so dass ihm ermöglicht wird, von dem Betätigungselement vorbewegt zu werden und wiederum die Injektionsspritze aus ihrer zurückgezogenen Position in ihre ausgefahrene Position vorbewegt und ihre Inhalte durch die Auslassdüse auszugeben, bewegbar ist; und ein Arretierelement, das zwischen einer Sperrposition, in der es die Bewegung des Auslösers aus seiner Ruheposition in seine aktive Position verhindert, und einer Freigabeposition, in der es die Bewegung des Auslösers aus seiner Ruheposition in seine aktive Position erlaubt, wobei der Auslöser danach in seiner aktiven Position gehalten wird, bewegbar ist.

**11. Injektionsvorrichtung nach einem der Ansprüche 5-7, die weiter aufweist:**

einen Auslöser, der aus einer Ruheposition, in der er bewirkt, dass das Treiberelement in einer Position, die der zurückgezogenen Position der Injektionsspritze entspricht, gehalten wird, in eine Betriebsposition, in der er nicht länger bewirkt, dass das Treiberelement derart zurückgehalten wird, so dass ihm ermöglicht wird, von dem Betätigungselement vorbewegt zu werden und wiederum die Injektionsspritze aus ihrer zurückgezogenen Position in ihre ausgefahrene Position vorbewegt und ihre Inhalte durch die Auslassdüse auszugeben, bewegbar ist; und ein Arretierelement, das das Primärelement aufweist, wobei das Arretierelement zwischen einer Sperrposition, in der es die Bewegung des Auslösers aus seiner Ruheposition in seine aktive Position verhindert und das Primärelement aus der Austrittsöffnung ragt, und einer Freigabeposition, in der es die Bewegung des Auslösers aus seiner Ruheposition in seine aktive Position erlaubt und das Primärelement nicht aus der Austrittsöffnung ragt oder in einem geringeren Ausmaß daraus ragt, wobei der Auslöser danach in seiner aktiven Position gehalten wird, bewegbar ist.

**12. Injektionsvorrichtung nach Anspruch 10 oder Anspruch 11, bei der der Auslöser ein Sperrelement aufweist, das in der Ruheposition des Auslösers an einer Sperrfläche des Treiberelementes angreift und es in der aktiven Position nicht tut.**

**13. Injektionsvorrichtung nach einem der Ansprüche 10 - 12, bei der der Auslöser und das Arretierelement**

einen Vorsprung und einen Durchlass umfassen, wobei der Vorsprung mit dem Durchlass ausgerichtet ist, wenn das Arretierelement in seiner Freigabeposition ist, sonst jedoch nicht, so dass es dem Auslöser erlaubt ist, sich durch Bewegung des Vorsprungs in den Durchlass aus seiner Ruheposition in seine aktive Position zu bewegen.

**14. Injektionsvorrichtung nach Anspruch 13, bei der sich der Vorsprung auf dem Auslöser befindet und sich der Durchlass in dem Arretierelement befindet.**

**15. Injektionsvorrichtung nach einem der Ansprüche 10 -14, bei der der Auslöser und eine weitere Komponente der Vorrichtung einen sperrenden Vorsprung und eine entsprechende sperrende Fläche, gegen die der sperrende Vorsprung sperrt, wenn der Auslöser in seiner aktiven Position ist, umfassen.**

**16. Injektionsvorrichtung nach Anspruch 15, bei der sich der sperrende Vorsprung auf dem Auslöser befindet.**

**17. Injektionsvorrichtung nach Anspruch 15 oder Anspruch 16, bei der die genannte weitere Komponente der Vorrichtung das Arretierelement ist.**

**Revendications**

**1. Dispositif d'injection, comprenant :**

■ un boîtier (112) adapté pour recevoir une seringue (114) ayant une buse de décharge (118) et ayant une tétine (123) qui recouvre sa buse de décharge, de sorte que la seringue est mobile entre une position rétractée dans laquelle la buse de décharge est contenue à l'intérieur du boîtier et une position étendue dans laquelle la buse de décharge s'étend à partir du boîtier en passant par une ouverture de sortie (128), le boîtier comprenant des moyens pour solliciter (126) la seringue de sa position étendue à sa position rétractée ;

■ un mécanisme de blocage amovible qui retient la seringue dans sa position rétractée ; et

■ un élément de fermeture de boîtier (111) qui peut occuper une première position, dans laquelle il se positionne sur le boîtier et empêche la libération du mécanisme de blocage, et une seconde position dans laquelle il n'empêche pas la libération du mécanisme de blocage, la première position de l'élément de fermeture de boîtier étant une position dans laquelle il met en prise la tétine, de sorte que le mouvement de l'élément de fermeture de boîtier jusqu'à sa seconde position se traduit par le retrait de la tétine de la seringue ;

■ un actionneur (130) ;

- un dispositif d'entraînement (131) qui est déclenché par l'actionneur et qui agit à son tour sur la seringue pour la faire avancer de sa position rétractée à sa position étendue et pour décharger son contenu par la buse de décharge ;
- un mécanisme de libération pouvant fonctionner pour libérer le mécanisme de blocage, permettant ainsi à la seringue d'avancer grâce à l'actionneur, de sa position rétractée à sa position étendue, et dans lequel la première position de l'élément de fermeture de boîtier est une position dans laquelle il empêche le mécanisme de libération d'être actionné ; et
- un mécanisme de retour, activé lorsque le dispositif d'entraînement a atteint une position de retour nominale, pour libérer la seringue de l'action de l'actionneur, suite à quoi les moyens de sollicitation ramènent la seringue à sa position rétractée ; **caractérisé en ce que :**
- le mécanisme de blocage comprend un élément de verrouillage (161) qui est positionné à l'intérieur du boîtier et est sollicité dans une position dans laquelle il met en prise une surface de blocage (163) et le mécanisme de libération le déplace de cette position dans une position dans laquelle il ne met plus la surface de blocage en prise.
2. Dispositif d'injection selon la revendication 1, dans lequel la première position de l'élément de fermeture de boîtier est une position dans laquelle il ferme l'ouverture de sortie de la buse de décharge et la seconde position est une position dans laquelle il ne le fait pas.
  3. Dispositif d'injection selon la revendication 1 ou la revendication 2, dans laquelle la première position de l'élément de fermeture de boîtier est une position dans laquelle il se positionne sur le boîtier et la seconde position est une position dans laquelle il ne le fait pas.
  4. Dispositif d'injection selon l'une quelconque des revendications précédentes, dans lequel l'élément de fermeture de boîtier est un capuchon (111) qui est positionné sur le boîtier.
  5. Dispositif d'injection selon la revendication 1, dans lequel le mécanisme de libération est un élément principal (119) mobile entre des positions de blocage et de libération et dans lequel la première position de l'élément de fermeture de boîtier est une position dans laquelle il recouvre l'élément principal.
  6. Dispositif d'injection selon la revendication 5, dans lequel la position de blocage de l'élément principal est une position dans laquelle il fait saillie de l'ouverture de sortie et la position de libération est une position dans laquelle il ne fait pas saillie de l'ouverture de sortie ou bien fait saillie de celle-ci sur une moindre étendue.
  7. Dispositif d'injection selon la revendication 6, dans lequel l'élément principal est un manchon (119).
  8. Dispositif d'injection selon la revendication 6 ou la revendication 7, dans lequel l'élément principal comprend une ouverture de verrouillage (165) à travers laquelle l'élément de verrouillage fait saillie avant qu'il ne mette en prise la surface de blocage, l'élément principal agissant en tant que came et l'élément de verrouillage en tant que poussoir de came, de sorte que le mouvement de l'élément principal de sa position de blocage à sa position de libération amène l'élément de verrouillage à se dégager de la surface de blocage.
  9. Dispositif d'injection selon la revendication 8, dans lequel l'élément de verrouillage comprend une surface à rampe (167) contre laquelle une surface de l'élément principal sert à la dégager de la surface de blocage.
  10. Dispositif d'injection selon l'une quelconque des revendications 1 à 7, comprenant en outre :
    - un déclencheur mobile d'une position de repos dans laquelle il amène le dispositif d'entraînement à être retenu dans une position correspondant à la position rétractée de la seringue, à une position active dans laquelle il n'amène plus le dispositif d'entraînement à être retenu, lui permettant ainsi d'être avancé par l'actionneur et à son tour de faire avancer la seringue de sa position rétractée à sa position étendue et de décharger son contenu par la buse de décharge ; et
    - un élément d'enclenchement mobile entre une position de blocage dans laquelle il empêche le mouvement du déclencheur de sa position de repos à sa position active et une position de libération à laquelle il permet le mouvement du déclencheur de sa position de repos à sa position active, le déclencheur étant ensuite retenu dans sa position active.
  11. Dispositif d'injection selon l'une quelconque des revendications 5 à 7, comprenant en outre :
    - un déclencheur mobile d'une position de repos dans laquelle il amène le dispositif d'entraînement à être retenu dans une position correspondant à la position rétractée de la seringue, à une position opérationnelle dans laquelle il

n'amène plus le dispositif d'entraînement à être ainsi retenu, lui permettant ainsi d'être avancé par l'actionneur et à son tour de faire avancer la seringue de sa position rétractée à sa position étendue et décharger son contenu par la buse de décharge ; et

■ un élément d'enclenchement comprenant l'élément principal, l'élément d'enclenchement étant mobile entre une position de blocage dans laquelle il empêche le mouvement du déclencheur de sa position de repos à sa position active et l'élément principal fait saillie de l'ouverture de sortie, et une position de libération dans laquelle il permet le mouvement du déclencheur de sa position de repos à sa position active et l'élément principal ne fait pas saillie de l'ouverture de sortie ou bien fait saillie de celle-ci sur une moindre étendue, le déclencheur étant ensuite retenu dans sa position active.

12. Dispositif d'injection selon la revendication 10 ou la revendication 11, dans lequel le déclencheur comprend un élément de blocage qui, dans la position de repos du déclencheur, met en prise une surface de blocage du dispositif d'entraînement et, dans la position active, ne le fait pas.
13. Dispositif d'injection selon l'une quelconque des revendications 10 à 12, dans lequel le déclencheur et l'élément d'enclenchement comprennent une saillie et une ouverture, la saillie étant alignée avec l'ouverture lorsque l'élément d'enclenchement est dans sa position de libération, mais pas autrement, permettant ainsi au déclencheur de passer de sa position de repos à sa position active par le mouvement de la saillie dans l'ouverture.
14. Dispositif d'injection selon la revendication 13, dans lequel la saillie est sur le déclencheur et l'ouverture est dans l'élément d'enclenchement.
15. Dispositif d'injection selon l'une quelconque des revendications 10 à 14, dans lequel le déclencheur et un autre composant du dispositif comprennent une saillie de verrouillage et une surface de verrouillage correspondante contre laquelle la saillie de verrouillage se verrouille lorsque le déclencheur est dans sa position active.
16. Dispositif d'injection selon la revendication 15, dans lequel la saillie de verrouillage est sur le déclencheur.
17. Dispositif d'injection selon la revendication 15 ou la revendication 16, dans lequel ledit autre composant du dispositif est le dispositif d'enclenchement.

FIG. 1




FIG. 2





FIG. 3










FIG. 6









**REFERENCES CITED IN THE DESCRIPTION**

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

**Patent documents cited in the description**

- US 5599309 A [0001]
- WO 9535126 A [0001]
- WO 05070481 A [0001]
- EP 0516473 A [0001]
- US 20050203466 A [0003]
- US 6077247 A [0003]